Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

Methods in Enzymology

Volumn 593, Issue , 2017, Pages 175-198

  Fernández Ruiz, Javier ^a,b,c   Gómez Ruiz, María ^a,b,c   García, Concepción ^a,b,c   Hernández, Mariluz ^a,b,c   Ramos, José A ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

Cannabinoids; Chronic progressive neurodegenerative disorders; Endocannabinoids; Neurodegeneration; Neuroprotection; Neurorepair

Indexed keywords

CANNABINOID; ENDOCANNABINOID; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; CANNABINOID RECEPTOR;

CLINICAL ASSESSMENT; CYTOTOXICITY; DEGENERATIVE DISEASE; DEVELOPED COUNTRY; DRUG EFFECT; DRUG TARGETING; EXPERIMENTAL ANIMAL; GLIA CELL; HUMAN; NERVE CELL; NEUROPROTECTION; NONHUMAN; SPECIES DIFFERENTIATION; ANIMAL; DISEASE MODEL; METABOLISM; PRECLINICAL STUDY;

ANIMALS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, CANNABINOID;

EID: 85021697926     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/bs.mie.2017.06.021     Document Type: Chapter

References (89)

1. Alhouayek, M., Muccioli, G.G., COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends in Pharmacological Sciences 35 (2014), 284–292.
2. Aranda-Anzaldo, A., Dent, M.A., Why cortical neurons cannot divide, and why do they usually die in the attempt?. Journal of Neuroscience Research 95 (2017), 921–929.
3. Arevalo-Martin, A., Molina-Holgado, E., Garcia-Ovejero, D., Cannabinoids to treat spinal cord injury. Progress in Neuro-Psychopharmacology & Biological Psychiatry 64 (2016), 190–199.
4. Athauda, D., Foltynie, T., The ongoing pursuit of neuroprotective therapies in Parkinson's disease. Nature Reviews. Neurology 11 (2015), 25–40.
5. Baune, B.T., Inflammation and neurodegenerative disorders: Is there still hope for therapeutic intervention?. Current Opinion in Psychiatry 28 (2015), 148–154.
6. Benito, C., Nuñez, E., Tolon, R.M., et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of Neuroscience 23 (2003), 11136–11141.
7. Berk, C., Paul, G., Sabbagh, M., Investigational drugs in Alzheimer's disease: Current progress. Expert Opinion on Investigational Drugs 23 (2014), 837–846.
8. Bisogno, T., Hanus, L., De Petrocellis, L., et al. Molecular targets for cannabidiol and its synthetic analogues: Effects on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology 134 (2001), 845–852.
9. Carrier, E.J., Kearn, C.S., Barkmeier, A.J., et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Molecular Pharmacology 65 (2004), 999–1007.
10. 9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathology and Applied Neurobiology 38 (2012), 535–547.
11. Cheng, H.C., Ulane, C.M., Burke, R.E., Clinical progression in Parkinson disease and the neurobiology of axons. Annals of Neurology 67 (2010), 715–725.
12. Choi, I.Y., Ju, C., Anthony Jalin, A.M., et al. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. The American Journal of Pathology 182 (2013), 928–939.
13. Chung, J.H., Seo, A.Y., Chung, S.W., et al. Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Research Reviews 7 (2008), 126–136.
14. Coates, J.R., Wininger, F.A., Canine degenerative myelopathy. The Veterinary Clinics of North America. Small Animal Practice 40 (2010), 929–950.
15. Costa, L., Amaral, C., Teixeira, N., Correia-da-Silva, G., Fonseca, B.M., Cannabinoid-induced autophagy: Protective or death role?. Prostaglandins & Other Lipid Mediators 122 (2016), 54–63.
16. Demuth, H.U., Dijkhuizen, R.M., Farr, T.D., Gelderblom, M., Horsburgh, K., Iadecola, C., et al. Recent progress in translational research on neurovascular and neurodegenerative disorders. Restorative Neurology and Neuroscience 35 (2017), 87–103.
17. Divers, T.J., Mohammed, H.O., Cummings, J.F., Equine motor neuron disease. The Veterinary Clinics of North America. Equine Practice 13 (1997), 97–105.
18. Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 (2007), 384–386.
19. Duarte, J.M., Ferreira, S.G., Carvalho, R.A., Cunha, R.A., Köfalvi, A., CB₁ receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus. Neurochemistry International 60 (2012), 1–8.
20. Eaton, S.L., Wishart, T.M., Bridging the gap: Large animal models in neurodegenerative research. Mammalian Genome, 2017, 10.1007/s00335-017-9687-6 in press.
21. Esposito, G., De Filippis, D., Maiuri, M.C., et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neuroscience Letters 399 (2006), 91–95.
22. Esposito, G., Scuderi, C., Savani, C., et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. British Journal of Pharmacology 151 (2007), 1272–1279.
23. Esposito, G., Scuderi, C., Valenza, M., et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One, 6, 2011, e28668.
24. Fagan, S.G., Campbell, V.A., The influence of cannabinoids on generic traits of neurodegeneration. British Journal of Pharmacology 171 (2014), 1347–1360.
25. Fernández-Ruiz, J., Moro, M.A., Martínez-Orgado, J., Cannabinoids in neurodegenerative disorders and stroke/brain trauma: From preclinical models to clinical applications. Neurotherapeutics 12 (2015), 793–806.
26. Fernández-Ruiz, J., Romero, J., Ramos, J.A., Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. Handbook of Experimental Pharmacology 231 (2015), 233–259.
27. Fernández-Ruiz, J., Romero, J., Velasco, G., et al. Cannabinoid CB2 receptor: A new target for controlling neural cell survival?. Trends in Pharmacological Sciences 28 (2007), 39–45.
28. Fernández-Ruiz, J., Sagredo, O., Pazos, M.R., et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?. British Journal of Clinical Pharmacology 75 (2013), 323–333.
29. Fidaleo, M., Fanelli, F., Ceru, M.P., Moreno, S., Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands. Current Medicinal Chemistry 21 (2014), 2803–2821.
30. Fowler, C.J., Rojo, M.L., Rodriguez-Gaztelumendi, A., Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?. Experimental Neurology 224 (2010), 37–47.
31. Frade, J.M., Ovejero-Benito, M.C., Neuronal cell cycle: The neuron itself and its circumstances. Cell Cycle 14 (2015), 712–720.
32. Frisoni, G.B., Jack, C.R. Jr., Winblad, B., Alzheimer's disease biomarker development: A call to funding bodies (special issue-roadmap to Alzheimer's biomarkers in the clinic). Neurobiology of Aging 52 (2017), 117–118.
33. Fujii, M., Sherchan, P., Krafft, P.R., Rolland, W.B., Soejima, Y., Zhang, J.H., Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats. Journal of the Neurological Sciences 342 (2014), 101–106.
34. Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M., Maccarrone, M., Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in Lipid Research 52 (2013), 633–650.
35. García, M.C., Cinquina, V., Palomo-Garo, C., Rábano, A., Fernández-Ruiz, J., Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neuroscience Letters 587 (2015), 1–4.
36. Geldenhuys, W.J., Van der Schyf, C.J., Rationally designed multi-targeted agents against neurodegenerative diseases. Current Medicinal Chemistry 20 (2013), 1662–1672.
37. Gómez, O., Arévalo-Martin, A., García-Ovejero, D., et al. The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation. Glia 58 (2010), 1913–1927.
38. Gómez, O., Sanchez-Rodriguez, A., Le, M., et al. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. British Journal of Pharmacology 163 (2011), 1520–1532.
39. Grimm, A., Eckert, A., Brain aging and neurodegeneration: From a mitochondrial point of view. Journal of Neurochemistry, 2017, 10.1111/jnc.14037 in press.
40. Hampson, A.J., Bornheim, L.M., Scanziani, M., et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. Journal of Neurochemistry 70 (1998), 671–676.
41. Hiebel, C., Behl, C., The complex modulation of lysosomal degradation pathways by cannabinoid receptors 1 and 2. Life Sciences 138 (2015), 3–7.
42. Holm, I.E., Alstrup, A.K., Luo, Y., Genetically modified pig models for neurodegenerative disorders. The Journal of Pathology 238 (2016), 267–287.
43. Hoque, A., Hossain, M.I., Ameen, S.S., Ang, C.S., Williamson, N., Ng, D.C., et al. A beacon of hope in stroke therapy-Blockade of pathologically activated cellular events in excitotoxic neuronal death as potential neuroprotective strategies. Pharmacology & Therapeutics 160 (2016), 159–179.
44. Hwang, J., Adamson, C., Butler, D., Janero, D.R., Makriyannis, A., Bahr, B.A., Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sciences 86 (2010), 615–623.
45. Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., Steardo, L., Cannabidiol: A promising drug for neurodegenerative disorders?. CNS Neuroscience & Therapeutics 15 (2009), 65–75.
46. Jones, E.G., Mendell, L.M., Assessing the decade of the brain. Science, 284, 1999, 739.
47. Jüttler, E., Potrovita, I., Tarabin, V., et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology 47 (2004), 580–592.
48. Kallendrusch, S., Kremzow, S., Nowicki, M., Grabiec, U., Winkelmann, R., Benz, A., et al. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia 61 (2013), 1822–1831.
49. Kang, K.W., Lee, S.J., Kim, S.G., Molecular mechanism of nrf2 activation by oxidative stress. Antioxidants & Redox Signaling 7 (2005), 1664–1673.
50. Kaplan, B.L., The role of CB1 in immune modulation by cannabinoids. Pharmacology & Therapeutics 137 (2013), 365–374.
51. Khan, T.A., Hassan, I., Ahmad, A., Perveen, A., Aman, S., Quddusi, S., et al. Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders. CNS & Neurological Disorders Drug Targets 15 (2016), 310–320.
52. Kowal, S.L., Dall, T.M., Chakrabarti, R., Storm, M.V., Jain, A., The current and projected economic burden of Parkinson's disease in the United States. Movement Disorders 28 (2013), 311–318.
53. 9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-β/STAT proinflammatory pathways in BV-2 microglial cells. The Journal of Biological Chemistry 285 (2010), 1616–1626.
54. Kudelova, J., Fleischmannova, J., Adamova, E., Matalova, E., Pharmacological caspase inhibitors: Research towards therapeutic perspectives. Journal of Physiology and Pharmacology 66 (2015), 473–482.
55. Lanciego, J.L., Barroso-Chinea, P., Rico, A.J., Conte-Perales, L., Callén, L., Roda, E., et al. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. Journal of Psychopharmacology 25 (2011), 97–104.
56. Leweke, F.M., Piomelli, D., Pahlisch, F., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, 2012, e94.
57. 1. Journal of Neurochemistry 80 (2002), 448–456.
58. Mazucanti, C.H., Cabral-Costa, J.V., Vasconcelos, A.R., Andreotti, D.Z., Scavone, C., Kawamoto, E.M., Longevity pathways (mTOR, SIRT, insulin/IGF-1) as key modulatory targets on aging and neurodegeneration. Current Topics in Medicinal Chemistry 15 (2015), 2116–2138.
59. McLellan, M.A., Rosenthal, N.A., Pinto, A.R., Cre-loxP-mediated recombination: General principles and experimental considerations. Current Protocols in Mouse Biology 7 (2017), 1–12.
60. Mechoulam, R., Shohami, E., Endocannabinoids and traumatic brain injury. Molecular Neurobiology 36 (2007), 68–74.
61. Mechoulam, R., Spatz, M., Shohami, E., Endocannabinoids and neuroprotection. Science's STKE, 2002, 2002, re5.
62. Molina-Holgado, F., Pinteaux, E., Moore, J.D., et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. The Journal of Neuroscience 23 (2003), 6470–6474.
63. Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., et al. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. The Journal of Neuroscience 22 (2002), 9742–9753.
64. Morton, A.J., Howland, D.S., Large genetic animal models of Huntington's disease. Journal of Huntington's Disease 2 (2013), 3–19.
65. Oh, Y.T., Lee, J.Y., Lee, J., et al. Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NFκB activation in BV2 murine microglial cells. Neuroscience Letters 474 (2010), 148–153.
66. Ohno-Shosaku, T., Kano, M., Endocannabinoid-mediated retrograde modulation of synaptic transmission. Current Opinion in Neurobiology 29C (2014), 1–8.
67. Pacher, P., Mechoulam, R., Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Progress in Lipid Research 50 (2011), 193–211.
68. Pryce, G., Riddall, D.R., Selwood, D.L., Giovannoni, G., Baker, D., Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. Journal of Neuroimmune Pharmacology 10 (2015), 281–292.
69. Rodríguez-Cueto, C., Benito, C., Fernández-Ruiz, J., et al. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. British Journal of Pharmacology 171 (2014), 1472–1489.
70. Rodríguez-Cueto, C., Benito, C., Romero, J., Hernández-Gálvez, M., Gómez-Ruiz, M., Fernández-Ruiz, J., Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Pathobiology 81 (2014), 149–159.
71. Rodríguez-Cueto, C., Hernández-Gálvez, M., Hillard, C.J., Maciel, P., García-García, L., Valdeolivas, S., et al. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. Neuroscience 339 (2016), 191–209.
72. Saba, L., Imaging in neurodegenerative disorders. 2015, Oxford University Press, USA.
73. Sampaio, C., Borowsky, B., Reilmann, R., Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. Movement Disorders 29 (2014), 1419–1428.
74. Sarne, Y., Asaf, F., Fishbein, M., Gafni, M., Keren, O., The dual neuroprotective-neurotoxic profile of cannabinoid drugs. British Journal of Pharmacology 163 (2011), 1391–1401.
75. Shohami, E., Mechoulam, R., A non-psychotropic cannabinoid with neuroprotective properties. Drug Development Research 50 (2000), 211–215.
76. Smith, S.R., Terminelli, C., Denhardt, G., Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. The Journal of Pharmacology and Experimental Therapeutics 293 (2000), 136–150.
77. Stahel, P.F., Smith, W.R., Bruchis, J., Rabb, C.H., Peroxisome proliferator-activated receptors: “Key” regulators of neuroinflammation after traumatic brain injury. PPAR Research, 2008, 2008, 538141.
78. Stella, N., Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58 (2010), 1017–1030.
79. United Nations, Available at: esa.un.org/unpd/wpp/publications/files/key_findings_wpp_2015.pdf, 2015.
80. Valdeolivas, S., Pazos, M.R., Bisogno, T., Piscitelli, F., Iannotti, F.A., Allarà, M., et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death & Disease, 4, 2013, e862.
81. Van Sickle, M.D., Duncan, M., Kingsley, P.J., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005), 329–332.
82. Vendel, E., de Lange, E.C., Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier. Neuromolecular Medicine 16 (2014), 620–642.
83. Walter, L., Franklin, A., Witting, A., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. The Journal of Neuroscience 23 (2003), 1398–1405.
84. Wang, Y., Ma, S., Wang, Q., et al. Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. Science China. Life Sciences 57 (2014), 201–208.
85. Whitelaw, C.B., Sheets, T.P., Lillico, S.G., Telugu, B.P., Engineering large animal models of human disease. The Journal of Pathology 238 (2016), 247–256.
86. World Health Organization, Aging and life course. Available at: www.who.int/ageing/about/facts/en, 2013.
87. Yang, W., Tu, Z., Sun, Q., Li, X.J., CRISPR/Cas9: Implications for modeling and therapy of neurodegenerative diseases. Frontiers in Molecular Neuroscience, 9, 2016, 30.
88. Youssef, S.A., Capucchio, M.T., Rofina, J.E., Chambers, J.K., Uchida, K., Nakayama, H., et al. Pathology of the aging brain in domestic and laboratory animals, and animal models of human neurodegenerative diseases. Veterinary Pathology 53 (2016), 327–348.
89. Ziemka-Nałęcz, M., Zalewska, T., Endogenous neurogenesis induced by ischemic brain injury or neurodegenerative diseases in adults. Acta Neurobiologiae Experimentalis 72 (2012), 309–324.